Lumos Pharma (LUMO) Earnings Date & Reports

A.I. Advisor

published Earnings

LUMO is expected to report earnings to fall 28.49% to -66 cents per share on November 12

Lumos Pharma LUMO Stock Earnings Reports

Q3'24

Est.

$-0.67

Q2'24

Beat

by $0.24

Q1'24

Missed

by $0.30

Q4'23

Missed

by $3.04

Q3'23

Beat

by $0.11

The last earnings report on August 01 showed earnings per share of -93 cents, beating the estimate of -116 cents. With 140.98K shares outstanding, the current market capitalization sits at 30.14M.

View a ticker or compare two or three

Compare

LUMO

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For LUMO
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a clinical-stage biopharmaceutical company, which engages in the development of therapeutics for the treatment of Pediatric Growth Hormone Deficiency (PGHD)

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

4200 Marathon Boulevard

Phone

+1 512 215-2630

Employees

Web

https://www.lumos-pharma.com